Hepatic GSTM3 deficiency Accelerates Atherosclerosis through redox-driven mitochondrial dysfunction and necroinflammation in Apoe−/− mice
- 5 May 2026
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 417, 120764
Abstract
No abstract availableKeywords
Funding Information
- CSIR – Indian Institute of Chemical Biology (MLP-115)
- CSIR – Indian Institute of Chemical Biology (OLP-115)
- Indian Association for the Cultivation of Science
- Council of Scientific and Industrial Research, India
- CSIR - Indian Institute of Chemical Biology
- Anusandhan National Research Foundation (SPR/2023/000358)
This publication has 33 references indexed in Scilit:
- FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver diseaseClinical Nutrition, 2024
- DAMPs and DAMP-sensing receptors in inflammation and diseasesImmunity, 2024
- Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex mattersJournal of Hepatology, 2023
- Self-transfecting GMO-PMO chimera targeting Nanog enable gene silencing in vitro and suppresses tumor growth in 4T1 allografts in mouseMolecular Therapy Nucleic Acids, 2023
- Mitochondrial alterations in fatty liver diseasesJournal of Hepatology, 2022
- Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implicationsJournal of Hepatology, 2016
- Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein ProfileClinical Gastroenterology and Hepatology, 2015
- Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based studyHepatology, 2015
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Adenosine triphosphate: enzymatic spectrophotometric determinationThe Journal of Nutritional Biochemistry, 1990